Nathaniel S Treister1, Michael Nieder2, Christina Baggott3, Ellen Olson4, Tammy Lo5, Xichen Jin6, Yun Gao7, Lu Chen8, Ha Dang9, Lillian Sung10. 1. Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, MA, USA. 2. Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. 3. Pediatric Hematology-Oncology, Stanford Medical Center, Stanford, CA, USA. 4. Children's Healthcare of Atlanta, Aflac Cancer and Blood Disorders Center, Atlanta, GA, USA. 5. Department of Research and Evaluation, Kaiser Permanente, Pasadena, CA, USA. 6. Data Operations, Global Drug Development, Novartis, Shanghai, China. 7. Children's Oncology Group, Monrovia, CA, USA. 8. Division of Biostatistics, City of Hope, Duarte, CA, USA. 9. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. 10. Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Abstract
OBJECTIVE: The objective was to describe the reliability and validity of the healthcare professional proxy-report version of the Children's International Mucositis Evaluation Scale (ChIMES). METHODS: We included pediatric patients who were between 4 and 21 years of age and scheduled to undergo hematopoietic cell transplantation. Mucositis was evaluated by trained healthcare professionals who scored ChIMES, the World Health Organization oral toxicity scale, mouth, and throat pain visual analogue scale, National Cancer Institute-Common Terminology Criteria and the Oral Mucositis Daily Questionnaire. Measures were completed daily and evaluated on days 7-17 post-stem cell infusion for this analysis. Psychometric properties examined were internal consistency, test-retest reliability (days 13 and 14), and convergent construct validity. RESULTS: There were 192 participants included. Cronbach's alpha was 0.90 for ChIMES Total Score and 0.93 for ChIMES Percentage Score. Test-retest reliability were as follows: intraclass correlation coefficient (ICC) 0.82 (95% confidence interval (CI) 0.77-0.85) for ChIMES Total Score and ICC 0.82 (95% CI 0.77-0.86) for ChIMES Percentage Score. In terms of construct validation, all correlations between measures met or exceeded those hypothesized (all p < 0.05). CONCLUSIONS: The healthcare professional proxy-report version of ChIMES is reliable and valid for children and adolescents undergoing hematopoietic cell transplantation.
OBJECTIVE: The objective was to describe the reliability and validity of the healthcare professional proxy-report version of the Children's International Mucositis Evaluation Scale (ChIMES). METHODS: We included pediatric patients who were between 4 and 21 years of age and scheduled to undergo hematopoietic cell transplantation. Mucositis was evaluated by trained healthcare professionals who scored ChIMES, the World Health Organization oral toxicity scale, mouth, and throat pain visual analogue scale, National Cancer Institute-Common Terminology Criteria and the Oral Mucositis Daily Questionnaire. Measures were completed daily and evaluated on days 7-17 post-stem cell infusion for this analysis. Psychometric properties examined were internal consistency, test-retest reliability (days 13 and 14), and convergent construct validity. RESULTS: There were 192 participants included. Cronbach's alpha was 0.90 for ChIMES Total Score and 0.93 for ChIMES Percentage Score. Test-retest reliability were as follows: intraclass correlation coefficient (ICC) 0.82 (95% confidence interval (CI) 0.77-0.85) for ChIMES Total Score and ICC 0.82 (95% CI 0.77-0.86) for ChIMES Percentage Score. In terms of construct validation, all correlations between measures met or exceeded those hypothesized (all p < 0.05). CONCLUSIONS: The healthcare professional proxy-report version of ChIMES is reliable and valid for children and adolescents undergoing hematopoietic cell transplantation.
Authors: Deborah Tomlinson; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; Lillian Sung Journal: Support Care Cancer Date: 2007-08-28 Impact factor: 3.603
Authors: Deborah Tomlinson; Marie-Chantal Ethier; Peter Judd; John Doyle; Adam Gassas; Ahmed Naqvi; Lillian Sung Journal: Eur J Cancer Date: 2010-10-12 Impact factor: 9.162
Authors: Deborah Tomlinson; Faith Gibson; Nathaniel Treister; Christina Baggott; Peter Judd; Eleanor Hendershot; Anne-Marie Maloney; John Doyle; Brian Feldman; Lillian Sung Journal: Support Care Cancer Date: 2008-11-04 Impact factor: 3.603
Authors: Adeela Usman; Sarah Lewis; Kathryn Hinsliff-Smith; Annabelle Long; Gemma Housley; Jake Jordan; Heather Gage; Tom Dening; John R F Gladman; Adam L Gordon Journal: Age Ageing Date: 2019-05-01 Impact factor: 10.668